Proton pump inhibitors induced fungal dysbiosis in patients with gastroesophageal reflux disease

被引:5
作者
Shi, Yichao [1 ,2 ]
Li, Jianfeng [2 ]
Cai, Shuntian [2 ]
Zhao, Hong [3 ]
Zhao, Huijun [2 ]
Sun, Gang [2 ]
Yang, Yunsheng [2 ,4 ]
机构
[1] Peking Univ, Aerosp Ctr Hosp, Dept Gastroenterol, Aerosp Sch Clin Med, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Gastroenterol & Hepatol, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Neurol, Beijing, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China
来源
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY | 2023年 / 13卷
关键词
gastroesophageal reflux disease; proton pump inhibitor; fecal mycobiota; Candida; gastric mucosal mycobiota; LONG-TERM USE; CANDIDA-ALBICANS; COMMENSAL FUNGI; THERAPY; MICROBIOME; RISK; INFLAMMATION; PROPHYLAXIS; MEDICATION; ESOPHAGUS;
D O I
10.3389/fcimb.2023.1205348
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Gut mycobiota inhabits human gastrointestinal lumen and plays a role in human health and disease. We investigated the influence of proton pump inhibitors (PPIs) on gastric mucosal and fecal mycobiota in patients with gastroesophageal reflux diseases (GERD) by using Internal Transcribed Spacer 1 sequencing. A total of 65 participants were included, consisting of the healthy control (HC) group, GERD patients who did not use PPIs (nt-GERD), and GERD patients who used PPIs, which were further divided into short-term (s-PPI) and long-term PPI user (l-PPI) groups based on the duration of PPI use. The alpha diversity and beta diversity of gastric mucosal mycobiota in GERD patients with PPI use were significantly different from HCs, but there were no differences between s-PPI and l-PPI groups. LEfSe analysis identified Candida at the genus level as a biomarker for the s-PPI group when compared to the nt-GERD group. Meanwhile, Candida, Nothojafnea, Rhizodermea, Ambispora, and Saccharicola were more abundant in the l-PPI group than in the nt-GERD group. Furthermore, colonization of Candida in gastric mucosa was significantly increased after PPI treatment. However, there was no significant difference in Candida colonization between patients with endoscopic esophageal mucosal breaks and those without. There were significant differences in the fecal mycobiota composition between HCs and GERD patients regardless whether or not they used PPI. As compared to nt-GERD patient samples, there was a high abundance of Alternaria, Aspergillus, Mycenella, Exserohilum, and Clitopilus in the s-PPI group. In addition, there was a significantly higher abundance of Alternaria, Aspergillus, Podospora, Phallus, and Monographella in the l-PPI group than nt-GERD patients. In conclusion, our study indicates that dysbiosis of mycobiota was presented in GERD patients in both gastric mucosal and fecal mycobiota. PPI treatment may increase the colonization of Candida in the gastric mucosa in GERD patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Metoclopramide, H2 Blockers, and Proton Pump Inhibitors: Pharmacotherapy for Gastroesophageal Reflux in Neonates
    Malcolm, William F.
    Cotten, C. Michael
    CLINICS IN PERINATOLOGY, 2012, 39 (01) : 99 - +
  • [32] Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors
    Johnson, David A.
    Levy, Benjamin H., III
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (09) : 1541 - 1548
  • [33] Increased Proximal Reflux in a Hypersensitive Esophagus Might Explain Symptoms Resistant to Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease
    Rohof, Wout O.
    Bennink, Roelof J.
    de Jonge, Hugo
    Boeckxstaens, Guy E.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (10) : 1647 - 1655
  • [34] Endoscopic measurement of gastric pH is associated with persistent acid reflux in patients treated with proton pump inhibitors for gastroesophageal reflux disease
    Januszewicz, Wladyslaw
    Hartley, James
    Waldock, William
    Roberts, Geoffrey
    Alias, Bincy
    Hobson, Anthony
    Wernisch, Lorenz
    di Pietro, Massimiliano
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2019, 7 (10) : 1389 - 1398
  • [35] Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study)
    Lu, Bin
    Zhang, Ling
    Wang, Jiangbin
    Wang, Bangmao
    Zou, Xiaoping
    Fei, Guijun
    Chen, Dongfeng
    Wang, Xuehong
    Wu, Bin
    Zou, Duowu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (10) : 1722 - 1727
  • [36] Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole
    Mermelstein, Joseph
    Mermelstein, Alanna Chait
    Chait, Maxwell M.
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2016, 9 : 163 - 172
  • [37] A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease
    Shimizu, Yasuo
    Dobashi, Kunio
    Kobayashi, Setsuo
    Ohki, Ichiro
    Tokushima, Masahiko
    Kusano, Motoyasu
    Kawamura, Osamu
    Shimoyama, Yasuyuki
    Utsugi, Mitsuyoshi
    Sunaga, Noriaki
    Ishizuka, Tamotsu
    Mori, Masatomo
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2006, 209 (03) : 181 - 189
  • [38] Endoscopic grading of gastroesophageal flap valve helps predict proton pump inhibitor response in patients with gastroesophageal reflux disease
    Cheong, Jae Hoon
    Kim, Gwang Ha
    Lee, Bong Eun
    Choi, Moon Ki
    Moon, Ji Yoon
    Ryu, Dong Yup
    Kim, Dong Uk
    Song, Geun Am
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2011, 46 (7-8) : 789 - 796
  • [39] Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review
    Miyazaki, Hirota
    Igarashi, Ataru
    Takeuchi, Toshihisa
    Teng, Lida
    Uda, Akihito
    Deguchi, Hisato
    Higuchi, Kazuhide
    Tango, Toshiro
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (08) : 1316 - 1328
  • [40] Putting Out the Fire: The Relationship of Pharmacogenetics and Proton Pump Inhibitors for the Treatment of Gastroesophageal Reflux Disease
    Zheng, Connor L.
    Alzghari, Saeed K.
    CUREUS, 2018, 10 (05):